Board of directors

Fredrik Sjövall

Chairman of the Board

Chairman of the Board since 2020 (board member since 2018). Trained civil engineer in automation technology and a master’s degree in business development.

Born: 1980

Experience: Fredrik has 15 years of experience in positions as CEO and Chairman of companies in the Life Science industry. Previous positions include CEO of Inhalation Sciences AB, PharmaSurgics AB (now Promore Pharma AB) and Hemcheck AB.

Ongoing assignments: Chairman of the Board of Ziccum AB, Monivent AB, and Emollivet AB. Board member of Axelero AB and Phargentis AB.

Previous assignments in the last five years: Chairman of Hemcheck Sweden AB, Inhalation Sciences Sweden AB and Ectin Research AB.

Holding in the Company: 40,000 shares (privately and through company).

Fredrik Sjövall is independent in relation to the Company and the Company’s largest owner.

Ola Flink

Board member

Board member since 2017 (Chairman of the Board 2017-2020). Pharmacy degree.

Born: 1944

Experience: Ola has nearly 50 years of experience from the pharmaceutical industry, including Astra Zeneca, ACO Pharmaceuticals, and as a consultant regarding drug development and experience as an investor in Life Science. Ola is a board member (and former chairman) of Asarina Pharma AB (publ.), listed on Nasdaq First North.

Ongoing assignment: Chairman of Pens. Pharmaceutical Association. Board member of Asarina Pharma AB (publ.) and in Ola Flink Consulting AB. Member of the Nomination Committee for Brf Tullstugan 3.

Previous assignments in the past five years: Board member of Umecrine Cognition AB, Marbileads AS Norway, and Asarina Pharma AB (publ).

Owns more than five percent of the shares in: Ola Flink Consulting AB.

Holding in the Company: 482,001 shares (privately and through company).

Ola Flink is independent in relation to the Company and the Company’s largest owner.

Jan Holmbäck

Chief Scientific Officer

Chief Scientific Officer since 2010. Doctoral degree in organic chemistry.

Born: 1957

Experience: Jan is a co-founder of Lipidor and has almost 40 years of experience in drug development, especially in analytical and organic chemistry.

Ongoing assignments: Chairman of the board of the Swedish Society for Nature Conservation in Vaxholm. CEO and board member of SumIT System Aktiebolag.

Previous assignments in the last five years:

Owns more than five percent of the shares in: SumIT System AB and Lipidor AB.

Holdings in the Company: 818,811 shares.

Vibhu Rinwa

Program Manager

Vibhu Rinwa has a Doctoral degree in Pharmaceutical Sciences started working with Lipidor in 2018.

Born: 1986

Experience: Vibhu has been able to acquire a large amount of knowledge in formulation science and gained broad experience in pre-clinical and clinical development. She has worked on drug delivery in different complex dosage form designs for New Chemical Entities and value-added generics.

Ongoing assignments:

Previous assignments in the last five years:

Owns more than five percent of the shares in:

Holdings in the Company: 35,755